Allogene Therapeutics
APR 2 0 18 Allogene acquires Pfizer’s allogeneic CAR T portfolio and closes one of the largest Series A rounds in biotechnology history— $300 million from a premier investment consortium that includes Two River, TPG, Vida Ventures, Bellco Capital, the University of California Office of the Chief Investment Officer of the Regents, Gilead, and Pfizer OCT 2 0 18 Public company debut, raising $372.
Basic Information
- Category: Cell Therapy
- Founded: 2017
- Headquarters: South San Francisco, CA
- Website: allogene.com
Documented Facts
- Phone: 650-457-2700 (No linked source recorded for this statement.)
- Email: //info@allogene.com (No linked source recorded for this statement.)
- Country: Public (No linked source recorded for this statement.)
- Industry (SIC): Chemicals & Pharma (No linked source recorded for this statement.)
- Stock ticker: ALLO (Nasdaq) (No linked source recorded for this statement.)
Evidence and Sources
- Allogene Therapeutics — Official Site (official)
- Allogene Therapeutics on linkedin (social)
- Allogene Therapeutics, Inc. — SEC EDGAR (reference)
Citation Guidance
Explore Cell Therapy profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Allogene Therapeutics.
- Canonical profile: https://brandsource.ai/brands/allogene-therapeutics
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/allogene-therapeutics/json-ld
- Citation profile API: https://brandsource.ai/api/brands/allogene-therapeutics/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (94/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2025-10-28T04:26:05.738Z
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
APR 2 0 18 Allogene acquires Pfizer’s allogeneic CAR T portfolio and closes one of the largest Series A rounds in biotechnology history— $300 million from a premier investment consortium that includes Two River, TPG, Vida Ventures, Bellco Capital, the University of California Office of the Chief Investment Officer of the Regents, Gilead, and Pfizer OCT 2 0 18 Public company debut, raising $372.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 2 supporting sources linked.
- 5 structured facts available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.